artículo
Xanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters
Fecha
2011Registro en:
10.1016/j.healun.2010.10.003
1053-2498
MEDLINE:21145258
WOS:000288924200007
Autor
Greig, Douglas
Alcaino, Hernan
Castro, Pablo F.
Garcia, Lorena
Verdejo, Hugo E.
Navarro, Mario
Lopez, Rafael
Mellado, Rosemarie
Tapia, Fabiola
Gabrielli, Luigi A.
Nogerol, Camilo
Chiong, Mario
Godoy, Ivan
Lavandero, Sergio
Institución
Resumen
BACKGROUND: Increased oxidative stress in heart failure (HF) leads to inflammation and endothelial dysfunction (ED). Both statins and allopurinol have known anti-oxidant properties, but their utility in HF has not been fully assessed. METHODS: This investigation was a prospective, double-blind, double-dummy study, performed between March 2007 and June 2009. Seventy-four HF patients, with New York Heart Association (NYHA) Class II or III status and left ventricular ejection fraction (LVEF) <40%, were included. Patients received placebo during 4 weeks and were then randomized to receive 4 weeks of either atorvastatin 20 mg/day plus placebo (ATV+PLA group) or atorvastatin 20 mg/day orally plus allopurinol 300 mg/day orally (ATV +ALLO group). Malondialdehyde (MDA), extracellular superoxide dismutase (ecSOD) activity and uric acid (UA) levels, among others, were determined at baseline and after 4 weeks of treatment. ED was assessed by flow-dependent endothelial-mediated vasodilation (FDD), and functional capacity by 6-minute walk test (6MWT). RESULTS: Thirty-two patients were randomized to ATV+PLA and 38 to ATV+ALLO. Mean age was 59 +/- 2 years, 82% were male, and 22% had an ischemic etiology. Hypertension was present in 60% and diabetes in 15% of those studied. No significant differences were observed between baseline measurements and after placebo. After 4 weeks of treatment, both groups showed a significant decrease on MDA (0.9 +/- 0.1 to 0.8 +/- 0.1 and 1.0 +/- 0.5 to 0.9 +/- 0.1 mu mol/liter, p = 0.88), UA (7.4 +/- 0.4 to 6.8 +/- 0.3 and 7.2 +/- 0.4 to 5.0 +/- 0.3 mg/dl, p <0.01) and FDD (3.9 +/- 0.2% to 5.6 +/- 0.4% and 4.6 +/- 0.3% to 7.1 +/- 0.5%, p = 0.07) with increased ecSOD activity (109 +/- 11 to 173 +/- 13 and 98 +/- 10 to 202 +/- 16. U/ml/min, p = 0.41) and improved 6MWT (447 +/- 18 to 487 +/- 19 and 438 +/- 17 to 481 +/- 21 m, p = 0.83), with all values for ATV +PLA and ATV+ALLO, respectively; p-values are for comparison between groups after treatment. CONCLUSION: Short-term ATV treatment in heart failure (HF) patients reduces oxidative stress and improves FDD and functional capacity. These beneficial effects are not strenghthened by the addition of alopurinol. J Heart Lung Transplant 2011;30:408-13 (C) 2011 International Society of Heart and Lung Transplantation. All rights reserved.